Specifically, alterations in the B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF), mitogen-activated protein kinase (MAPK), A-Raf Proto-Oncogene, Serine/Threonine Kinase (ARAF), and Rat Sarcoma Viral Oncogene Homolog (RAS) pathways have been identified in RDD, presenting potential therapeutic targets (6). This evidence concerns the gene WNK2 and sinus histiocytosis with massive lymphadenopathy.